Alzheimer’s Disease/Dementia News

Alzamend Neuro Inc. announced initiation of a phase 1/2a clinical trial for its proprietary immunotherapy vaccineALZN002 to treat mild to moderate dementia associated with Alzheimer’s disease.

Air pollution may be a risk factor for dementia, according to the findings of a meta-analysis published in BMJ.

The descendants of Estée Lauder donated $200 million to the Alzheimer’s Drug Discovery Foundation to help prevent, diagnose, treat and cure the disease, according to a press release.

Biogen Inc. has reported promising data from a phase 1b trial of BIIB080, an investigational antisense oligonucleotide therapy that reduced soluble tau protein in cerebrospinal fluid in patients with early Alzheimer’s disease.

Alzheon Inc. has announced positive interim findings from an ongoing phase 2 study evaluating ALZ-801, an investigational disease-modifying treatment for Alzheimer’s disease.

Among older patients with atrial fibrillation and dementia, apixaban was associated with lower risk for stroke and major bleeding vs. dabigatran, rivaroxaban or warfarin, researchers reported.

A clinical biopharmaceutical company has announced completion of the clinical portion of its phase 2a multiple ascending dose study examining safety and tolerability of AL001 for dementia related to Alzheimer’s disease.

The Veterans’ Health Administration will provide coverage of a drug for the treatment of Alzheimer’s disease to veterans with early stages of the disease, according to a press release from the drug’s manufacturer.

With the increasing number of available treatments for Alzheimer’s disease, it is important for patients with cognitive concerns to openly communicate with their doctors, the Alzheimer’s Association said in a press release.

The emergence of visual artistic creativity among those with frontotemporal dementia may be linked to early lesion-induced activation of the visual cortex and may depend on environment or genetics, according to research presented in JAMA Neurology.